2025-03-04
minor
Study Status, Oversight v13
Primary completion date2024-01→2026-01
Completion date2025-10→2026-10
2024-01-22
notable
Recruiting→Active, Not Recruiting Study Status, Contacts/Locations v12
Trial statusRecruiting→Active, Not Recruiting
Primary completion dateestimated 2023-12→confirmed 2024-01
Study sitesdetails revised at 12 of 12 sites
Show 10 earlier versions
2023-05-23
minor
Study Status, Sponsor/Collaborators v10
Primary completion date2023-04→2023-09
2022-05-02
minor
Study Status v9
Primary completion date2022-01→2023-04
Completion date2024-07→2025-10
2021-07-23
minor
Study Status, Oversight, Study Design, Arms and Interventions, Eligibility v8
PhaseNot applicable→Not specified
2021-05-10
minor
Study Status, Sponsor/Collaborators, Contacts/Locations v7
Study sitescontacts updated at 1 of 12 sites
2021-02-01
minor
Study Status v6
Primary completion date2021-01→2022-01
Completion date2023-07→2024-07
2019-12-17
minor
Study Status, Contacts/Locations, IPDSharing v5
Primary completion date2020-01→2021-01
Completion date2022-07→2023-07
Study sites11→12
2018-08-23
minor
Study Status, Outcome Measures, Eligibility, Contacts/Locations v4
Eligibility criteria+132 characters
Inclusion Criteria:
Age -- Age ≤ 30 years at time of initial qualifying solid tumor diagnosis
Diagnosis -- Histologic diagnosis of solid malignancy (excluding brain tu [...] ent material to meet the minimum requirements for profiling; OR
Patient has already had molecular profiling and patient has not yet started matched targeted therapy based on the report .
Exclusion Criteria:
- No Therapy Planned
-- Patients who have declined further anticancer therapy will be excluded.
- Performance Status
-- Patients with Lansky (age < 16 years) or Karnofsky (age ≥16 years) score < 50 will be excluded.
- Life Exp [...] [...]
2017-05-31
minor
Study Identification, Study Status, Study Description, Study Design, Arms and Interventions, Eligibility, Contacts/Locations, IPDSharing v3
PhaseNot specified→Not applicable
Study sites5→10
Eligibility criteria+20 characters
[...] having an expected event free survival of < 50% at 2 years.
Lacks definitive diagnosis or classical genomic findings after histologic review and standard molecular testing (rare tumor group).
Examples include (eligibility not limited to these examples):
Histology typically associated with a fusion in which fusion is not detected.
Ewing-like sarcoma
Undiffere [...] Specimen Samples
Sufficient tumor specimen available to meet [...] ent material to meet the minimum requirements for profiling; --- OR
Patient has already had molecular profiling demonstrating a potentially targetable variant in a laboratory certi [...] [...]
Study description-11 characters
Patients with extra-cranial (not in the brain) solid tumors that are ateither highdifficult riskto for recurrencediagnose or thatmore has already recurred or become refractorydifficult to standard treatmenttreat are eligible to participate in this study.
All enrolled pat [...]
Study title+43 characters
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
2016-11-06
minor
Study Status, Contacts/Locations v2
2016-03-04
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start date2015-09→2015-10
Study sitesdetails revised at 2 of 2 sites